Last updated: February 23, 2026
What is NDC 70436-0011?
National Drug Code (NDC) 70436-0011 refers to Velexbru (voclosporin), a calcineurin inhibitor approved by the FDA in August 2021 for the treatment of lupus nephritis (LN) in adult patients. Developed by Aurinia Pharmaceuticals, this drug is positioned as a targeted immunosuppressant intended for a specific patient subset.
Market Overview
Indication and Target Demographic
Velexbru is indicated for adult patients with active or severe lupus nephritis, affecting approximately 1.5 million Americans with systemic lupus erythematosus (SLE) and an estimated 65,000 to 70,000 cases of LN annually in the U.S. (Petri et al., 2012). The drug targets primarily post-refractory patients or those intolerant to conventional immunosuppressants like cyclophosphamide or mycophenolate mofetil.
Competitive Landscape
The primary rival is Rituxan (rituximab), off-label, with limited FDA-approved options for LN. The only FDA-approved drugs for LN before Velexbru were CellCept (mycophenolate mofetil) and Benlysta (belimumab), with Rituxan used off-label in refractory cases.
Market Penetration
In its first year (2022), Aurinia targeted sales in the U.S. with a pipeline expansion to Europe and Asia. Initial market uptake was slow due to high pricing, limited clinician familiarity, and competition from established therapies.
Pricing Analysis
Amazon and US Market
The wholesale acquisition cost (WAC) for Velexbru is set at approximately $36,600 per year for a typical maintenance dose, which aligns with other biologics targeting rare autoimmune conditions (Aurinia Pharmaceuticals, 2022).
| Aspect |
Details |
| WAC per year |
~$36,600 |
| Cost per infusion (monthly dosing) |
$3,050 (assumed 12 infusions annually) |
| Price strategy |
Premium, justified by clinical benefits |
Insurance and Reimbursement
Reimbursement models are complex, involving PBMs, payers, and specialty pharmacy channels. Out-of-pocket costs depend on coverage but can reach $5,000–$7,500 annually after insurance.
Price Trends
Since launch, Velexbru's price has remained stable, with minimal discounts or patient assistance programs. Future price increases are unlikely without new indications or expanded formulations.
Revenue Projections
Short-term (2023–2025)
Market penetration is projected at 3–5% of eligible LN patients in the U.S. within the first 3 years, with ongoing growth as prescribing physicians become familiar with the drug.
| Year |
Estimated U.S. Patients |
Revenue (USD millions) |
Assumptions |
| 2023 |
1,200 |
$44 |
2% market penetration, 50% treatment rate |
| 2024 |
3,600 |
$132 |
5% market penetration, 55% treatment rate |
| 2025 |
5,400 |
$198 |
8% market penetration, 60% treatment rate |
Long-term (2026+)
Market share could reach 10–15% if the drug demonstrates substantial benefits over competitors, expanding to international markets with a projected treatment population of 5,000 LN patients annually.
Key Market Drivers and Risks
Drivers
- FDA approval for the LN indication provided clinical validation.
- Growing awareness of the drug’s efficacy and safety.
- Potential for expanded indications in SLE.
Risks
- High cost may limit access and adoption.
- Competition from biosimilars and off-label uses.
- Reimbursement uncertainties could affect revenue.
Summary of Price and Market Assumptions
| Parameter |
Data/Comments |
| Launch Price |
~$36,600 WAC per year |
| Market Penetration (2023) |
2–3% of U.S. LN population |
| Revenue (2023) |
~$44 million |
| Long-term Market Share |
Up to 15% with expanded indications & acceptance |
Key Takeaways
NDC 70436-0011, Velexbru, commands a premium price aligned with specialty biologics, with initial annual revenue estimates around $44 million in 2023, rising to over $200 million by 2025 as market penetration grows. Price strategies remain stable, with growth dependent on clinical validation, reimbursement policies, and market expansion.
FAQs
Q1: How does Velexbru compare in price to competitors?
Velexbru’s price of ~$36,600 per year is comparable to other biologic treatments for autoimmune diseases, such as Benlysta (~$32,000 annually). It is higher than conventional immunosuppressants but justified by targeted indications and clinical benefits.
Q2: What factors could influence future price adjustments?
Introduction of new formulations, expanded indications, inflation, reimbursement environment, and market competition could impact pricing strategies.
Q3: What is the expected treatment adherence rate?
Approximately 55–60% of diagnosed LN patients are expected to adhere to Velexbru therapy, based on clinician insights and past biologic adherence patterns.
Q4: Which geographic markets offer the greatest growth potential?
The U.S. remains the largest market, but European countries and emerging Asian markets present significant growth avenues, especially where LN prevalence is high and biologics are reimbursed.
Q5: Are there patent or regulatory threats to Velexbru?
Patent exclusivity extends until at least 2030. Regulatory risks include potential side effect concerns or studies that could limit usage. No current threats are publicly known.
References
- Petri, M., et al. (2012). Lupus nephritis: clinical practice guidelines for diagnosis and management. The Lancet, 379(9819), 937–947.
- Aurinia Pharmaceuticals. (2022). Velexbru (voclosporin): Prescribing information.
- U.S. Food & Drug Administration. (2021). FDA approves Aurinia’s voclosporin for lupus nephritis.
